Abstract
After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 823-830 |
| Number of pages | 8 |
| Journal | Oncologist |
| Volume | 20 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jun 12 2015 |
Fingerprint
Keywords
- Carney-Stratakis syndrome
- Gastrointestinal stromal tumor
- GIST
- Imatinib
- KIT
- PDGFRA
- Regorafenib
- SDH
- Sunitinib
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Key issues in the clinical management of gastrointestinal stromal tumors : An expert discussion. / Maki, Robert G.; Blay, Jean Yves; Demetri, George D.; Fletcher, Jonathan A.; Joensuu, Heikki; In-Broto, Javiermart; Nishida, Toshirou; Reichardt, Peter; Schöffski, Patrick; Trent, Jonathan.
In: Oncologist, Vol. 20, No. 7, 12.06.2015, p. 823-830.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Key issues in the clinical management of gastrointestinal stromal tumors
T2 - An expert discussion
AU - Maki, Robert G.
AU - Blay, Jean Yves
AU - Demetri, George D.
AU - Fletcher, Jonathan A.
AU - Joensuu, Heikki
AU - In-Broto, Javiermart
AU - Nishida, Toshirou
AU - Reichardt, Peter
AU - Schöffski, Patrick
AU - Trent, Jonathan
PY - 2015/6/12
Y1 - 2015/6/12
N2 - After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.
AB - After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this article, we discuss important practice points that may impact upon questions of therapy of primary and metastatic GIST, with the hope that the questions addressed in this rare solid tumor can serve as examples of what can be achieved with kinase-directed therapies in other cancers. Wepresent cases that highlight some of the key issues in GIST management and afterward discuss both points of consensus and controversial issues in what is now recognizedas one of the most common forms of sarcoma.
KW - Carney-Stratakis syndrome
KW - Gastrointestinal stromal tumor
KW - GIST
KW - Imatinib
KW - KIT
KW - PDGFRA
KW - Regorafenib
KW - SDH
KW - Sunitinib
UR - http://www.scopus.com/inward/record.url?scp=84936879733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936879733&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2014-0353
DO - 10.1634/theoncologist.2014-0353
M3 - Article
VL - 20
SP - 823
EP - 830
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 7
ER -